Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ract in a process that ultimately results in the persistent inflammation underlying IBD. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the GI system.

"Current approaches to the treatment of Crohn's disease often result in serious side effects, especially following long-term use of these drugs," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "These results suggest that Traficet-EN has the potential to keep Crohn's patients in remission without complications such as broad immunosuppression associated with current therapies."

"Data generated from these two studies are groundbreaking in nature and have the potential to revolutionize the way Crohn's disease and ulcerative colitis are treated," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are particularly pleased that we have for the first time definitively identified the CCR9 chemokine ligand in the large bowel which will broaden the scope of digestive tract disorders that Traficet-EN could potentially treat successfully."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

The randomized, placebo-controlled, double-blind clinical trial of 436 patients is comprised of three discrete periods which allows for evaluation of efficacy and safety of Traficet-EN in inducing a cl
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI announced ... Hong Kong has been accredited by ... facility is the first clinical next-generation-sequencing laboratory to receive ... meeting the highest standard in clinical laboratory practices. Complementary to ... compliant laboratory process, and multiple ISO certifications, the CAP ...
(Date:7/1/2015)... , July 1, 2015 The ... group of state and regional professional rheumatology societies, ... of rheumatologists that explored perceptions of biosimilars and ... patients. Biosimilars are medicines that ... medicines. They are notably different from generic medications ...
(Date:7/1/2015)... , July 1, 2015 Eli Lilly and ... for the second quarter of 2015 on Thursday, July 23, ... day with the investment community and media to further detail ... begin at 9 a.m. EDT. Investors, media and the general ... through a link that will be posted on Lilly,s website ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of ... immunoassay segment of the In-Vitro Diagnostics market, announced the selection of ... a portable diagnostic platform designed to produce test results with central ... , , ...
... , June 21 ERT (Nasdaq: ... to the pharmaceutical, biotechnology and medical device industries, announced ... the Tufts Center for the Study of Drug Development, ... The industry-wide report measures the current and anticipated adoption ...
Cached Medicine Technology:CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 2CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 3CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer 4ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 2ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 3ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services 4
(Date:7/2/2015)... ... ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, as ... first poem, and three years later he was publishing an entire book of poetry. He ... world. "I have always believed that the best way to lift yourself up, is in ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have ... Their significant popularity has inspired four new, fun shades including: blue, lime, pink ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... The ZAC ... the 2015 swim season with important lessons on how to stay water safe with ... Who Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety ...
(Date:7/2/2015)... Dallas, TX (PRWEB) , ... ... ... “Negative pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information ... stages of development. Complete report on negative pressure wound therapy (NPWT) with ...
(Date:7/2/2015)... ... July 02, 2015 , ... Facial plastic surgery ... precision. There is an art and science that goes into successful facial reconstruction ... the facial features and lives of more than 2,500 satisfied facelift and neck ...
Breaking Medicine News(10 mins):Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3
... Wednesday, May 7, Cedar,Point amusement park/resort will host the ... this special event will benefit the,Firelands Chapter of the ... at Cedar Point,s Challenge Park and will,be a four-person, ... shotgun start at 4:30 p.m. Teams of four can ...
... are highly effective at preventing acute respiratory illness and ... worse, according to research published in the April issue ... , A study of 87 patients with chronic obstructive ... health and death - found that having the annual ...
... CDI Program Utilizing the Expertise of Two Industry ... ... 15 Precyse Solutions, the leader in,driving peak performance within Health ... robust service,offerings and highly qualified team of HIM experts. Noted professionals ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading ... aesthetic treatment systems, today announced that the company,will ... April 29, 2008,at 9:00 a.m. ET., On ... Davin and,Executive Vice President and Chief Financial Officer ...
... Benefits of Healthy, Wholesome Foods, JACKSONVILLE, Fla., April ... including those among children -- are at an all-time ... nutritional,information aimed at helping the youngest members of society ... resources like these,are few and far between., But ...
... they are to undergo screenings , , TUESDAY, April 15 ... women perceive their cancer risk may influence how likely ... cancer, says a University of California, San Francisco study. ... to 80, about breast, cervical and colon cancer. The ...
Cached Medicine News:Health News:Flu vaccines can reduce respiratory problems by up to 3/4 2Health News:Flu vaccines can reduce respiratory problems by up to 3/4 3Health News:Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues 2Health News:Cynosure to Announce First-Quarter 2008 Financial Results on April 29 2Health News:Professor Woodpecker Makes Children's Nutrition Fun and Simple 2Health News:Professor Woodpecker Makes Children's Nutrition Fun and Simple 3Health News:Women's Awareness of Cancer Risk Linked to Race, Ethnicity 2
... is a high precision optical system for ... the anterior eye segment, based on a ... Placido Disk. , GALILEI combines the advantages ... accuracy curvature data, while Scheimpflug imaging is ...
... The C-VUE 55 Toric Multifocal ... also have presbyopia with all day ... visual acuity at every distance. This ... wide range of parameters with ADDs ...
... Nicknamed the SRS, this new and innovative stent ... the office right at the chair with just ... medical grade silicone and is available in three ... separately). At each end of the stent is ...
... Using flying spot technology the Technolas 217z ... for personalized vision correction, allows surgeons in ... to -7.00 Diopters and astigmatism up to ... combines both a 2mm and 1mm truncated ...
Medicine Products: